There is no single “best inhaler” for pulmonary fibrosis because inhalers are not the primary treatment for this condition. Unlike asthma or COPD, where inhalers are the cornerstone of care, pulmonary fibrosis involves scarring of lung tissue rather than airway narrowing, so standard bronchodilator inhalers don’t address the underlying disease. The two internationally recommended treatments for idiopathic pulmonary fibrosis (IPF) are oral antifibrotic medications: pirfenidone and nintedanib. That said, certain inhaled therapies play a role in specific situations, and new inhaled options are in development.
Why Standard Inhalers Don’t Treat Fibrosis
Most inhalers you’d find at a pharmacy are designed to relax the muscles around your airways or reduce airway inflammation. Pulmonary fibrosis works differently. The lung tissue itself becomes thickened and stiff with scar tissue, making it harder for oxygen to pass into your bloodstream. A bronchodilator that opens airways won’t reverse or slow that scarring process.
International treatment guidelines from the American Thoracic Society and European Respiratory Society recommend pirfenidone and nintedanib as the only evidence-based therapies for IPF. Both are taken orally, not inhaled. They don’t cure fibrosis, but they slow the rate at which lung function declines. Inhaled N-acetylcysteine, once studied as a potential add-on therapy, is now conditionally recommended against as a standalone treatment for IPF due to lack of proven benefit.
When Bronchodilator Inhalers Can Help
Some people with pulmonary fibrosis also have obstructive airway conditions like COPD, asthma, or emphysema overlapping with their fibrosis. In one study of IPF patients, about 14% also had COPD and nearly 9% had asthma, and roughly 30% were using bronchodilator medications. For these patients, inhalers can relieve the airway-narrowing component of their breathing trouble even though they don’t touch the fibrosis itself.
Research has shown that IPF patients with small airway dysfunction (detectable through specialized breathing tests) experienced meaningful improvements in airflow and symptom scores after bronchodilator treatment. Patients without that airway component saw no benefit. This means bronchodilators aren’t helpful for every person with pulmonary fibrosis. They’re useful only when there’s a genuine obstructive element alongside the scarring. Your pulmonary function tests can help determine whether that applies to you.
Inhaled Treprostinil for Fibrosis With High Lung Pressure
The one FDA-approved inhaled therapy directly relevant to pulmonary fibrosis is treprostinil, sold as Tyvaso and Tyvaso DPI. This isn’t a bronchodilator. It’s a prostacyclin analogue, meaning it widens blood vessels in the lungs and reduces the strain on the right side of the heart. It’s specifically approved for people who have pulmonary hypertension caused by interstitial lung disease, a combination that’s common as fibrosis progresses.
The landmark trial published in the New England Journal of Medicine tested inhaled treprostinil against a placebo in patients with this combination of conditions. After 16 weeks, patients using inhaled treprostinil could walk about 31 meters farther in a six-minute walk test than those on placebo. That may sound modest, but in a population where exercise capacity steadily declines, any measurable improvement in walking distance is clinically significant. The study population included patients with IPF, combined pulmonary fibrosis and emphysema, and connective tissue disease-related lung scarring.
Tyvaso DPI is a dry powder inhaler version approved in 2022. If your doctor has identified elevated lung pressures alongside your fibrosis, this is currently the only inhaled medication with strong trial evidence behind it for that specific problem.
Inhaler Challenges for Fibrosis Patients
People with pulmonary fibrosis face a practical challenge with inhalers that doesn’t get discussed enough: generating enough breath force to use them properly. Dry powder inhalers require you to inhale forcefully enough to pull the medication deep into your lungs. Research shows you generally need a peak inspiratory flow rate of at least 60 liters per minute for optimal drug delivery from most dry powder devices. Patients with restrictive lung disease often struggle to reach that threshold because their stiff lungs can’t expand fully.
When inspiratory flow is too low, the powdered drug doesn’t break apart into particles fine enough to reach the small airways. In those cases, a nebulizer, which converts liquid medication into a mist you breathe in over several minutes, can deliver medication more effectively without requiring forceful inhalation. If you’ve been prescribed a dry powder inhaler and feel like it’s not working, this is worth raising with your care team. A simple test of your inspiratory flow can determine whether a nebulizer would serve you better.
Cough: A Common Barrier to Inhaled Therapy
Cough is already one of the most persistent symptoms of pulmonary fibrosis, occurring even more frequently than in asthma or COPD. Inhaled medications can make this worse. The lungs of people with fibrosis have heightened cough reflexes, partly driven by overactive nerve receptors in the airway lining. Inhaling any aerosolized substance can trigger prolonged coughing fits that make the treatment feel worse than the symptom it’s supposed to help.
Particle size matters. Research on IPF patients found that very small aerosol particles (under about 1.2 micrometers) did not trigger coughing, while larger particles reliably did. This suggests that the formulation and device matter as much as the drug itself. Nebulizers that produce a finer mist, or inhalers engineered for smaller particle output, may be better tolerated. If coughing makes an inhaled medication intolerable, ask about alternative formulations or delivery methods rather than simply stopping treatment.
Inhaled Antifibrotics in Development
One of the most promising developments is an inhaled version of pirfenidone, currently called AP01. Pirfenidone is already one of the two standard oral antifibrotic drugs, but the oral form causes significant side effects for many patients, particularly nausea and skin sensitivity to sunlight. Delivering it directly to the lungs could concentrate the drug where it’s needed while reducing those systemic side effects.
An early open-label trial led by researchers including Ganesh Raghu established initial dosing data. A larger Phase 2 trial is now recruiting 375 participants with progressive pulmonary fibrosis. The trial is testing two doses of inhaled pirfenidone against placebo, with the primary goal of measuring whether it slows the decline in lung capacity over 52 weeks. Secondary goals include tracking time to disease progression, quality of life scores, and changes in the amount of fibrosis visible on imaging. Results aren’t available yet, but if successful, this could eventually become the first inhaled treatment targeting the fibrosis itself rather than a complication of it.